Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR-hTNF + Doxorubicin in Advanced Ovarian Cancer
NCT00484432Phase 2Completed
- Sponsor
- AGC Biologics
- Start
- Nov 2008
- Primary completion
- Jun 2016
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of NGR-TNF in ovarian cancer, sponsored by AGC Biologics. Started Nov 2008; status: completed.
02
Drugs
NGR-TNF
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00484432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484432.